The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-first-class-drug-generalized-myasthenia-gravis-2025a1000z6f?src=rss
Author :
Publish date : 2025-12-15 19:11:00
Copyright for syndicated content belongs to the linked Source.
